^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    VisioCyt®

    Company:
    Atlanpole Biotherapies
    Type:
    CE Marked

    Details

    Evidence
    News
    VisioCyt® allows an earlier diagnosis of bladder cancer from a simple urine sample...This innovative solution is based on a patented technology combining fluorescence imaging and artificial intelligence.
    Cancer:
    Bladder Cancer
    Method:
    Fluorescence in situ hybridization (FISH)
    Approvals
    Date
    Cancer
    Gene
    Drug
    By
    02/06/20
    BC
    -
    CE